Collegium Pharmaceutical, Inc. cash flow to debt ratio of 35.01% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Collegium Pharmaceutical, Inc.'s free cash flow has increased 61.11% from $203.33M last year to $327.58M, signaling increasing performance

Collegium Pharmaceutical, Inc.'s debt to equity ratio is 2.75, which means that the company's assets are unhealthy financed, signaling financial risk.

Collegium Pharmaceutical, Inc.'s debt has decreased relative to shareholder equity from 3.75 last year to 2.75 today, signaling strengthened financials

Collegium Pharmaceutical, Inc. has a net debt to EBITDA ratio of 1.33x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Collegium Pharmaceutical, Inc.'s interest coverage ratio is 0.98, which means that the company struggles to meet interest obligations, signaling financial risk.

Collegium Pharmaceutical, Inc.'s profit margin has decreased (45.89%) in the last year from 10.96% to 5.93%, signaling decreasing performance

Collegium Pharmaceutical, Inc.'s short-term assets of $691.41M exceed its short-term liabilities of $440.03M

Collegium Pharmaceutical, Inc.'s return on assets of 2.24% is lower than the 5.00% threshold, indicating inefficient asset utilization

Collegium Pharmaceutical, Inc.'s return on equity of 15.96%, is higher than 15.00%, indicating good performance

Collegium Pharmaceutical, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Collegium Pharmaceutical, Inc. had positive net income in 4 out of 5 years, indicating stable and consistent earnings

Collegium Pharmaceutical, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Collegium Pharmaceutical, Inc. has a free cash flow yield of 37.13%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Collegium Pharmaceutical, Inc.'s yearly earnings has decreased 9.13% since last year from $69.19M to $62.87M, signaling decreasing performance

Collegium Pharmaceutical, Inc.'s yearly revenue has increased 23.62% since last year from $631.45M to $780.57M, signaling increasing performance

ROIC 6.10% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Collegium Pharmaceutical, Inc.'s 3-year revenue CAGR of 18.94% is positive, indicating growing revenue over the past 3 years

Collegium Pharmaceutical, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Collegium Pharmaceutical, Inc. had positive ROE in 4 out of 5 years, indicating consistent and reliable returns on equity

Collegium Pharmaceutical, Inc. has insufficient data to evaluate this check.

Collegium Pharmaceutical, Inc. has an earnings yield of 5.43%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Collegium Pharmaceutical, Inc. is undervalued relative to its fair value price of 66.69 based on EBITDA multiple model

Collegium Pharmaceutical, Inc. has an EV/EBITDA ratio of 3.53x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Collegium Pharmaceutical, Inc. is undervalued relative to its fair value price of 97.09 based on Earnings Fair Value model

Collegium Pharmaceutical, Inc. has a PEG-ratio over 1 which is considered overvalued

Collegium Pharmaceutical, Inc. has a price-to-book ratio of 2.83x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Collegium Pharmaceutical, Inc. has a price-to-sales ratio of 1.09x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue